Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist

BACKGROUND: Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Prostate Cancer Prostatic Dis
Egile Nagusiak: Margel, David, Ber, Yaara, Peer, Avivit, Shavit-Grievink, Liat, Pinthus, Jehonathan H., Witberg, Guy, Baniel, Jack, Kedar, Daniel, Rosenbaum, Eli
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8012206/
https://ncbi.nlm.nih.gov/pubmed/32737420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-020-0264-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak